Rihan El Bezawy
University of Milan
Clonogenic assayGene silencingCancerInternal medicineDownregulation and upregulationmicroRNAChemistryApoptosisImmunologySurvivinDU145MetastasisDiseaseProstate cancerC-MetCancer researchRadiation therapyMAPK/ERK pathwayRadioresistanceCell growthSignal transductionMedicineProtein kinase BBiology
12Publications
3H-index
120Citations
Publications 12
Newest
#1Silvia MartiniH-Index: 3
#2Valentina ZucoH-Index: 25
Last. Nadia ZaffaroniH-Index: 66
view all 10 authors...
Triple-negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Here, we pursued a combinatorial therapeutic approach to enhance the activity of selinexor, the first-in-class XPO1 inhibitor, by miR-34a ectopic expression in human TNBC experimental models. Anti-proliferative activity induced by selinexor and miR-34a expression, singly and in combination, was evaluated by MTS assay and cell counting. The effect of treatments on survivin and apoptosis-related protein...
Source
#1Paolo GandelliniH-Index: 25
Last. Nadia ZaffaroniH-Index: 66
view all 16 authors...
Active surveillance (AS) has evolved as a strategy alternative to radical treatments for very low risk and low-risk prostate cancer (PCa). However, current criteria for selecting AS patients are still suboptimal. Here, we performed an unprecedented analysis of the circulating miRNome to investigate whether specific miRNAs associated with disease reclassification can provide risk refinement to standard clinicopathological features for improving patient selection. The global miRNA expression profi...
Source
#1Valentina DoldiH-Index: 8
#2Rihan El BezawyH-Index: 3
Last. Nadia ZaffaroniH-Index: 66
view all 3 authors...
Prostate cancer (PCa) is the second most common tumor in men worldwide, and the fifth leading cause of male cancer-related deaths in western countries. PC is a very heterogeneous disease, meaning that optimal clinical management of individual patients is challenging. Depending on disease grade and stage, patients can be followed in active surveillance protocols or undergo surgery, radiotherapy, hormonal therapy, and chemotherapy. Although therapeutic advancements exist in both radiatiotherapy an...
1 CitationsSource
Background Dedifferentiated liposarcoma (DDLPS), a tumor that lacks effective treatment strategies and is associated with poor outcomes, expresses amplified MDM2 in the presence of wild-type p53. MDM2 ubiquitination of p53 facilitates its XPO1-mediated nuclear export, thus limiting p53 tumor suppressor functions. Consequently, nuclear export is a rational target in DDLPS. We directly compared the antitumor activity of the first-in class XPO1 inhibitor selinexor and doxorubicin, the standard fron...
1 CitationsSource
#1Rihan El BezawyH-Index: 3
#2Martina Tripari (University of Liverpool)H-Index: 1
Last. Nadia ZaffaroniH-Index: 66
view all 12 authors...
Speckle-type POZ (pox virus and zinc finger protein) protein (SPOP) is the most commonly mutated gene in prostate cancer (PCa). Recent evidence reports a role of SPOP in DNA damage response (DDR), indicating a possible impact of SPOP deregulation on PCa radiosensitivity. This study aimed to define the role of SPOP deregulation (by gene mutation or knockdown) as a radiosensitizing factor in PCa preclinical models. To express WT or mutant (Y87N, K129E and F133V) SPOP, DU145 and PC-3 cells were tra...
4 CitationsSource
#1Federica RotundoH-Index: 2
#2Denis CominettiH-Index: 14
Last. Paolo GandelliniH-Index: 25
view all 10 authors...
The development of novel therapies or the improvement of currently used approaches to treat prostate cancer (PCa), the most frequently diagnosed male tumor in developed countries, is an urgent need. In this regard, the functional characterization of microRNAs, molecules shown to regulate a number of cancer-related pathways, is instrumental to their possible clinical exploitation. Here, we demonstrate the tumor-suppressive role of the so far uncharacterized miR-1272, which we found to be signific...
3 CitationsSource
Background Radiotherapy is one of the main treatment options for non-metastatic prostate cancer (PCa). Although treatment technical optimization has greatly improved local tumor control, a considerable fraction of patients still experience relapse due to the development of resistance. Radioresistance is a complex and still poorly understood phenomenon involving the deregulation of a variety of signaling pathways as a consequence of several genetic and epigenetic abnormalities. In this context, c...
35 CitationsSource
#1Paolo GandelliniH-Index: 25
#2Rihan El BezawyH-Index: 3
Last. Nadia ZaffaroniH-Index: 66
view all 8 authors...
Radiotherapy is a standard treatment for organ-confined prostate cancer (PCa). Although treatment technical optimization has greatly improved local tumor control, a significant percentage of patients still undergo recurrence. The onset of radioresistance is a complex phenomenon involving several genetic and epigenetic abnormalities, including the deregulation of microRNAs (miRNAs), endogenous small noncoding RNA molecules that negatively regulate gene expression. In this study, we investigated t...
Source
#1Rihan El BezawyH-Index: 3
Last. Nadia ZaffaroniH-Index: 66
view all 7 authors...
Source
#1Rihan El BezawyH-Index: 3
#2Denis CominettiH-Index: 14
Last. Paolo GandelliniH-Index: 25
view all 12 authors...
Abstract Radiotherapy is one of the main treatment choices for non-metastatic prostate cancer (PCa), although development of radioresistance limits its effectiveness. Mounting evidence supports the ability of microRNAs to interfere with different radioresistance-associated pathways, suggesting their potential as radiosensitizers. Here, we demonstrate that reconstitution of miR-875-5p, whose expression is down-regulated in PCa clinical samples and directly correlates with that of E-cadherin, was ...
65 CitationsSource